Medium-term plans, capital spending, new plants, products and drug approvals from Japanese companies.
Nittoku has won a further order of about ¥10.2bn for humanoid-robot motor production equipment destined for North America, taking the project to about ¥18.4bn, with all revenue due from the year to March 2028.
Higher yields are widening the investment spread at Daiichi Life Group's main insurer, but the group's solvency ratio slipped to about 211% on surrender risk, and its full-year domestic equity sales estimate rose to about ¥900bn.
Eisai and Biogen launched a self-injectable weekly Leqembi pen in Japan at a listed ¥27,141 per pen, with first doses still given at a medical facility, MRI monitoring unchanged and Eisai's guidance untouched.
NHK Spring plans a roughly ¥15bn building at its Thai Welgrow plant for disk-drive suspensions, due December 2027 and outside its ¥15.4bn segment capex budget, in a half-year when the unit's sales rose 27.0%.
More than 550 accounting firms had decided to adopt freee's paid AI agents about two months after launch, but the company gives no revenue figure for them or for its new same-day invoice financing.
Renova has contracted all output of its 54.6MW Kumamoto wind project to Tokyo Gas for 25 years at above the feed-in tariff, though the price is undisclosed and the plant is not yet running.
Yokowo's board approved about ¥7.0bn of extra investment in probes and test sockets, taking its capacity plan to about ¥15.1bn, with a second Vietnam building due in February 2028 and the first brought forward to October 2027.
Mitsui Kinzoku will spend about ¥190bn on a Malaysian plant for MicroThin and VSP copper foil, funded from cash and borrowings, with staged start-up from April 2031, as it also lifts its dividend target to 4.0% of equity.
Marui Group plans a second revision of its installment and revolving fee rate, to between 18.0% and 19.8% in the year to March 2028 after an October 2025 rise to 18.0%, as interest expense rose to ¥4.3bn in the half; timing is undecided.
Japan Engine finished its first commercial hydrogen-fuel marine engine in September 2026 and plans to ship it in January, though building it dented interim engine sales while repair and parts income drove a raised full-year forecast.
Honda's planned Ohio plant, built for up to 240,000 cars a year and targeted to start in 2029, would raise its North American capacity from 1.67 million to 1.91 million units; the company calls the near-term earnings effect minor.
A Kawasaki Heavy Industries turbine that can run on 0% to 100% hydrogen is now installed at RWE's Emsland plant, but the emissions, durability and operability checks that would prove it still lie ahead.
Rohm's interim briefing moves its silicon carbide breakeven target forward by a year, while first-half server sales rose about 66% and full-year operating profit guidance stands at ¥50bn.
Three idle Yatsushiro paper machines will not restart after earthquake damage, Nippon Paper decided, while the mill's household-paper project is under review and new uses for the site are being studied.
Keisei Electric Railway has applied to the transport minister to lift fares 14.1% from March 2028 while holding student passes, scrapping the barrier-free fee and still showing a ¥8.18bn average loss under its own method.
Toyota will set up a robotics unit under its production chief and an education division led by its chairman from January 1, 2027, and replace regional heads in North America, China and Asia.
MSD has begun a Phase 1 trial of a PDPS-derived peptide candidate for inflammatory disease, and PeptiDream expects to book an undisclosed milestone fee as fourth-quarter revenue, already within its full-year forecast.
Mitsubishi Chemical Group has cancelled its exit from needle coke and pitch coke at Kagawa after finding it difficult to reach its carbon fiber targets with other companies' feedstock; production pauses in the business year beginning April 2027, with a restart expected a year later.
Kawasaki Kisen's five-year plan splits ¥700bn to ¥800bn in shareholder returns between a ¥120-a-share dividend worth ¥350bn and a flexible ¥350bn to ¥450bn, alongside a company-wide ROE target of 15% or more for 2031.
Hitachi Energy's investor-day decks put first-half sales at $11.0bn and backlog above $65bn, and lift the 2030 adjusted EBITA margin ambition to 19–21%, backed by a $9bn capacity programme and a data-centre order push.
Loadstar Capital's first real-estate security token, a ¥3.83bn Yokohama hotel offering launched in August, is treated as a financing and added no nine-month revenue, while net profit fell 12.2% and assets under management passed ¥200bn.
Nippon Kodoshi will invest about ¥15bn in a new Yonago line, raising separator capacity to roughly 1.3 times the current level for AI-server and data-centre demand, with operation planned from December 2028.
Central Japan Railway plans to lift the Nozomi charge to its approved ceiling in July 2027 and revise Green car charges in December 2027, estimating ¥50bn to ¥60bn a year in extra revenue.
Ibiden's board approved about ¥151bn of planned spending, centred on its Ogaki site in Gifu, to expand IC package substrates for CPUs, with sequential start-up and mass production planned from fiscal 2029.